Helena Linardou

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

Matthew D. Hellmann, Tudor–Eliade Ciuleanu, Adam Płużański et al. · New England Journal of Medicine · 2018 · 3.1K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

Adrianus J. de Langen, Melissa L. Johnson, Julien Mazières et al. · The Lancet · 2023 · 566 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

Luis Paz‐Ares, Suresh S. Ramalingam, Tudor–Eliade Ciuleanu et al. · Journal of Thoracic Oncology · 2021 · 322 citations · Full text

Pharmacy, Oncology, Pharmacology +17

ESMO Expert Consensus Statements on Cancer Survivorship: promoting high-quality survivorship care and research in Europe

Inês Vaz-Luís, Marianna Masiero, Guido Cavaletti et al. · Annals of Oncology · 2022 · 182 citations · Full text

Medicine, Oncology, Oncology Nursing +16

Somatic Mutations of the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor and Tyrosine Kinase Inhibitor Response to TKIs in Non-small Cell Lung Cancer: An Analytical Database

Samuel Murray, Issa J Dahabreh, Helena Linardou et al. · Journal of Thoracic Oncology · 2008 · 154 citations · Full text

Medicine, Oncology, Pharmacology +17